Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

November 1, 2020 | Poster
Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer
Prat et al, SITC, 2020
September 1, 2020 | Suggested Media
Pharma Tech Outlook: Top 10 Immunotherapy Companies of 2020
September 1, 2020 | Poster
A window-of-opportunity Study with atezolizumab and the oncolytic virus pelareorep in early Breast Cancer (REO-027, AWARE-1)
Prat et al, ESMO Breast Cancer, 2020
May 1, 2020 | Poster
Oncolytic virus Pelareorep [P] plus Carfilzomib & Dexamethasone [Kd] phase 1 trial in Carfilzomib-refractory patients (NCI9603): responses with cytokine storm
Sborov et al, ASCO, 2020
May 1, 2020 | Poster
CEACAM6 is a candidate biomarker for pelareorep resistance in pancreatic adenocarcinoma (PDAC)
Noonan Et al, ASCO GI, 2020
March 10, 2020 | Publication
Elucidation of pelareorep pharmacodynamics in a phase I trial in patients with KRAS mutated colorectal cancer
Goel et al, Molecular Cancer Therapeutics, 2020
January 1, 2020 | Publication
Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a Phase 1b study
Mahalingam et al, Clinical Cancer Research, 2019
December 1, 2019 | Poster
Carfilzomib Impairs the Innate Antiviral Immune Response and promotes cytotoxic T-cell Expansion in Oncolytic Virus Treated Multiple Myeloma Patients
Pichiorri Et al, ASH, 2019
November 1, 2019 | Poster
A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1)
Prat Et al, SITC, 2019
October 28, 2019 | Suggested Media
How has one of the most common cancers had such little innovation?
August 13, 2019 | Suggested Media
Biomarkers Are the Key for Realizing I-O’s True Potential
August 6, 2019 | Suggested Media
CEOCFO Magazine Interview with Dr. Matt Coffey
July 8, 2019 | Suggested Media
How Pelareorep Aids Checkpoint Blockade Therapy
June 1, 2019 | Publication
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam et al, Molecular Therapy Oncolytics, 2019
May 26, 2019 | Publication
Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)
Fountzilas et al, ASCO Abstract, 2019

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch